The World Parkinson Coalition® is a unique organization filling a niche in the global Parkinson's community by bringing the full spectrum of community members together both in person at triennial World Parkinson Congresses and virtually through many online educational programs.  Learn more at www.worldpdcoalition.org

By highlighting promising areas of research in the pipeline, the PDTrialTracker tool can help foster further collaboration between patients and researchers to accelerate the path to better treatments and a cure. Insights gained through analysis of the pipeline can help set research priorities, address roadblocks, enable greater patient involvement in trial design, and increase awareness of recruitment and funding needs.


Parkinson’s Disease Drug Therapies in the Clinical Trial Pipeline: 2022 Update

Review article, Journal of Parkinson's Disease, May 2022.

Authors: McFarthing, Kevin | Rafaloff, Gary | Baptista, Marco | Mursaleen, Leah | Fuest, Rosie | Wyse, Richard K. | Stott, Simon R.W.

Parkinson’s Disease Drug Therapies in the Clinical Trial Pipeline: 2021 Update
Review article, Journal of Parkinson's Disease, August 2021.
Authors: McFarthing, Kevin | Rafaloff, Gary | Baptista, Marco A.S. | Wyse, Richard K. | Stott, Simon R.W. 

Parkinson’s Disease Drug Therapies in the Clinical Trial Pipeline: 2020
Review article, Journal of Parkinson's Disease, July 2020.
Authors: McFarthing, Kevin | Buff, Susan | Rafaloff, Gary | Dominey, Thea | Wyse, Richard K. | Stott, Simon R.W. 

Suggestions for improving access to PD trial data to facilitate trial awareness, recruitment, and research efforts:

  1. adoption of a trial naming convention within the research/media/patient community that includes a trial's ClinicalTrials.gov trial ID # (NCT # - NCT followed by 8 digits) in all trial-related communications (clinic websites, recruiting efforts, media articles, etc.) (benefits: patients and the general public can easily access key trial information directly on ClinicalTrials.gov, easier to identify trial being referenced, easier to follow trial progress)
  2. trial teams to submit information for all PD studies (both interventional and observational), as well as RESULTS of completed studies, to ClinicalTrials.gov, whether submission is required or not. (benefits: free and open access to trial data, pipeline transparency, recruitment, collaboration, elimination of duplicate efforts, awareness of study outcomes amongst participants and community at large)
  3. trial teams to provide active trial listings on their medical center website when possible, even if it is only a listing of trial NCT numbers. (benefits: trial recruitment, trial awareness, aids collaboration)

This spreadsheet has 4 tabs/worksheets labeled: Phase 1 Trials, Phase 2 Trials, Phase 3 Trials, and Disease-Modifying Trials. The goal of the charts is to highlight key parameters and timelines for studies in the PD clinical trial pipeline to facilitate patient/researcher collaboration. Comments and feedback can be emailed to suebuff@outlook.com.

compiled by PD research advocates Sue Buff and Gary Rafaloff

This document provides an overview of disease-modifying therapies (therapies to slow, halt or reverse progression) currently in PD clinical trials (Phase 1, 2, 3), as well as a partial listing of upcoming clinical trials.  It includes links for access to more extensive information about the studies.

Analyzing the Parkinson's disease clinical trial pipeline to facilitate patient collaboration in research.